Anemia Treatment Market to Witness Healthy Competition Due to Increasing Product Consolidation Among Major Manufacturers
Over the years, the rise in consolidation activities, including drug development and new launches, mergers, agreements, collaborations, investments in research and development activities, and drug patent transfers among global leaders and regional players have been trademark for the overall competition in the global anemia treatment market.
Many global players are also setting up their manufacturing hubs and distribution channels in emerging countries such as China, India, and Brazil in order to increase their product potential and footprint in developing and poor economies. With continuous product launches and the aforesaid consolidated factors, the growth of the anemia treatment market is anticipated to surge during the forecast period.
Extensive Investments in R&D Activities by Key Drug Manufacturers to Bring Noble and Effective Medicaments into the Anemia Treatment Market
Key manufacturers in the anemia treatment market are constantly investing in research and development activities to design, develop, and introduce therapeutically-effective medicaments such as dietary supplements, erythrocyte simulating agents, antibiotics, chelating agents, and other biological products. Additionally, they are also upgrading their existing consumable product portfolios, ranging from dietary supplements to biological, so as to have a competitive edge in the market.
These companies are also trying to introduce new drugs for anemia treatment that will play a significant role in improving and providing quality healthcare in developing and poor economies. Drug manufacturers operating in the field of anemia treatment have also recorded strong financial growth over the last few years. For instance, Amgen’s Epoetin alpha used for the treatment of anemia chronic kidney disease has recorded significant growth since its market launch.
The company predicts that, the product revenue will further increase during the forecast period. Thus, an increase in the number of both, biologics and generic drugs by key manufacturers, and increasing research and development will contribute significantly towards the growth of the anemia treatment market during the forecast period.
Potential for Biosimilars for Anemia Treatment
Anemia of Chronic Kidney Disease (CKD) is the major disease in the anemia treatment market, and therefore, medicaments used for its treatment are the major revenue generating products in the market. It is considered that, the use of biologics such as erythropoietin stimulating agents (ESAs) will play a significant role in the anemia treatment market, globally.
The emergence of ESAs and rising demand for other biosimilar medications will bring new avenues of opportunities for drug manufacturers operating in the anemia treatment market. Biosimilar drugs have also become one of the cost-effective methods for anemia treatment. Besides, these products are readily available, globally, with highest patient access.
Over the years, there has been increase in FDA approval for various biosimilars for anemia treatment, and this has led to providing tremendous benefits to patients suffering from anemia of chronic kidney disease. For example, in 2018, the FDA approved Pfizer’s biosimilar - Epoetin Alfa (Retacrit), fostering a sustainable marketplace for biosimilars to treat anemia.
Major Agreements and Partnerships Among Key Drug Manufacturers for Anemia Treatment
With new developments and research activities in pharmaceutical industries, and biomedical research, medication efficacy to treat anemia and other diseases is also increasing, globally. To strengthen their product portfolio and develop noble drugs for anemia treatment, various drug manufacturers are building new business models to increase product revenue and prevent market loss.
Besides, new partnership-based models within drug manufacturers will help in adding new dimensions, and also reshape the research and development programs aimed at anemia treatment. In the last few years, activities such as mergers and partnerships within the pharmaceutical industry have continued to evolve, and have paved the way for drug development for anemia treatment.
Additionally, open collaborations and new product-based business models such as partnerships between drug manufacturers and regional distributors are expected to drive the anemia treatment market during the forecast period, leading to substantial regional growth. For more information, get in touch with our expert analyst.
Anemia Treatment Market: Competitive Landscape
This section of the anemia treatment market report features the profiles of key players operating in the anemia treatment market based on their differential strategies, anemia treatment product offerings, marketing approach, and company dashboard. Examples of some of the key players featured in this report include Amgen Inc., Hoffmann-La Roche Ltd, Pfizer Inc., Novartis AG, Janssen Pharmaceuticals, Inc. Teva Pharmaceutical Industries Ltd, AMAG Pharmaceuticals, Rockwell Medical, and Akebia Therapeutics, among others.
Key drug manufacturers in the anemia treatment market are focusing on marketing strategies to increase both, their product portfolio as well as geographical presence. Most of the companies operating in anemia medications are focused on aggressive pricing strategies in order to lead the market for anemia treatment.
Some other key market strategies followed by anemia treatment pharmaceutical companies include research and development agreements to increase product development, partnering with local as well as global retailers, and long-term partnerships with distribution sales such as institutional pharmacies, retail pharmacies, and mail-order pharmacies.
Anemia Treatment Market: Additional Questions Answered
Some of the additional questions addressed in this report on the anemia treatment market”
- What is the revenue potential of the anemia treatment markets across North America and Europe?
- Who are the key competitors and what are their portfolios in the anemia treatment market?
- What are the major challenges influencing the growth of the anemia treatment market?
- How is intervention from regulatory authorities shaping the growth of the anemia treatment market?
Research Methodology
The anemia treatment market has been estimated based on an epidemiology-based approach. The market was studied by estimating the base year market side in different region/countries. The market was estimated based on product dosage for treatment in the top 20 countries, globally. Other qualitative factors analyzed during market value estimation include awareness level of usage of anemia treatment medications including product usage, region, and prevalence of anemia.
This information was further validated with rigorous primary research (including interviews, surveys, in-person interactions, and viewpoints of seasoned analysts) and secondary research (including verified paid sources, authentic trade journals, and resourceful databases). The research study on the anemia treatment market also includes top trends and macro- as well as micro-economic factors shaping the anemia treatment market.
With this approach, the report on the anemia treatment market anticipates the industry attractiveness of every major segment in the anemia treatment market over the forecast period.
Key Segment
Based on treatment, the anemia treatment market is segmented into
- medications
- dietary supplements
Based on disease, the anemia treatment market is segmented into
- normocytic anemia
- microcytic anemia
- macrocytic anemia
Need specific information?
In the news
by - Sudip Saha, Managing Director and Co-Founder of Future Market Insights
Our Clients
View Our Reports from Healthcare
View Reports